Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026

B HONG KONG, April 6, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced that, at the 2026 European Lung Cancer Congress (ELCC 2026),…
posteditor
posteditor
Articles: 16137

Other News